JP2013136531A - Adiponectin production promoter - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an adiponectin production promoter which has high safety, can be used also as food and drink and has an excellent adiponectin production promotion effect.SOLUTION: The adiponectin production promoter includes at least either panaxatriol or panaxadiol. At least either the panaxatriol or panaxadiol is, preferably, the sapogenin of Araliaceae Panax ginseng obtained by subjecting Araliaceae Panax ginseng to hydrolysis treatment in the presence of an acid aqueous solution of 0.01 to 4 mol/L and lower alcohol.

Description

  The present invention relates to an adiponectin production promoter.

  Adiponectin is a secreted protein hormone that is secreted from fat cells, promotes fat burning in muscles (skeletal muscles), liver, etc., promotes sugar uptake into muscles, and synthesizes sugars in liver ( It has functions such as suppressing gluconeogenesis (see Non-Patent Documents 1 and 2).

  It is known that the concentration of adiponectin decreases in blood due to genetic factors, obesity, etc. This decrease in blood adiponectin concentration includes diabetes, hyperlipidemia, arteriosclerosis, hypertension and the like. It is known to have a strong correlation with lifestyle-related diseases.

  For example, it is disclosed that when the adiponectin is administered to a diabetic model mouse, insulin resistance is improved and the amount of neutral fat in serum is decreased (see Non-Patent Documents 2 and 3). Here, the insulin resistance is a phenomenon in which the responsiveness to insulin, which is a hormone that lowers blood glucose level, is deteriorated. The decrease in blood glucose level is a factor that causes type 2 diabetes, hyperlipidemia, hypertension and the like. One.

  It is also known to suppress arteriosclerosis when the adiponectin is overexpressed in an arteriosclerosis model mouse. Since this arteriosclerosis model mouse does not have a tendency for diabetes, it is considered that the arteriosclerosis-inhibiting action by adiponectin is caused by a route different from the route through diabetes (Non-Patent Documents 2 and 4). And 5).

  Examples of the adiponectin production promoter include thiazolidinedione antidiabetic agents (see Non-Patent Document 5). However, the thiazolidinedione antidiabetic agent has a problem that it has severe side effects such as heart failure and edema (see Non-Patent Documents 6 and 7).

  Therefore, at present, there is a strong demand for providing a new adiponectin production promoter that has high safety, can be used as a food and drink, and has an excellent adiponectin production promoting action.

Yamauchi T et al. , Nature Medicine, 2002 8 (11), 1288-1295. Record of the 128th Japan Medical Society Symposium “Adiponectin and Molecular Mechanisms of Diabetes / Cardiovascular Disease” Yamauchi T et al. , Nature Medicine, 2001 7 (8), 941-946. Yamauchi T et al. , Journal of Biological Chemistry, 2003 278 (4), 2461-2468, Epub 2002 Nov 12. Kadowaki T et al. , The Journal of Clinical Investigation, 2006, 116 (7), 1784-1792. "Actos (registered trademark) OD Tablet 15.30", package insert, Takeda Pharmaceutical Company Limited Yutaka Mori, “Latest Treatment of Diabetes” 2011, Vol. 2, no. 4. Fuji Medical Publishing

  An object of the present invention is to solve the above-described problems and achieve the following objects. That is, an object of the present invention is to provide an adiponectin production promoter that has high safety, can be used as a food and drink, and has an excellent adiponectin production promoting action.

Means for solving the problems are as follows. That is,
<1> An adiponectin production promoter characterized by containing at least one of panaxatriol and panaxadiol and promoting adiponectin production.
<2> The adiponectin production promoter according to <1>, wherein at least one of panaxatriol and panaxadiol is sapogenin derived from ginseng ginseng.
<3> Adiponectin production according to the above <2>, wherein sapogenin derived from the ginseng ginseng is obtained by hydrolyzing the ginseng ginseng in the presence of an acid aqueous solution of 0.01 mol / L to 4 mol / L and a lower alcohol. It is an accelerator.
<4> A food or drink comprising the adiponectin production promoter according to any one of <1> to <3>.

  According to the present invention, there is provided an adiponectin production promoter capable of solving the conventional problems, achieving the object, having high safety, being usable as a food and drink, and having an excellent adiponectin production promoting action. can do.

FIG. 1 is a diagram showing the action of panaxatriol and / or panaxadiol on blood adiponectin.

(Adiponectin production promoter)
The adiponectin production promoter of the present invention contains at least one of panaxatriol and panaxadiol, and further contains other components as necessary.

<Panaxatriol, Panaxadiol>
The panaxatriol (hereinafter sometimes abbreviated as “PT”) and the panaxadiol (hereinafter sometimes abbreviated as “PD”) are compounds belonging to danmaran triterpenes.

  The content of at least one of the PT and the PD in the adiponectin production promoter is not particularly limited and can be appropriately selected depending on the purpose.

The method for obtaining PT and / or PD is not particularly limited and may be appropriately selected depending on the intended purpose. For example, a plant containing saponin (hereinafter sometimes referred to as “saponin-containing plant”). The method of extracting from, the method of synthesize | combining, the method of using a commercial item etc. are mentioned.
Among these, a method obtained from a saponin-containing plant is preferable in that the PT and / or PD having high safety can be obtained. When the PT and / or PD is obtained from the saponin-containing plant, the PT and / or PD is obtained as an aglycon body (sapogenin) in which sugar is detached from the plant-derived saponin (glycoside) and the side chain is closed.

  The method for obtaining the PT and / or PD from the saponin-containing plant is not particularly limited and may be appropriately selected depending on the intended purpose. The saponin-containing plant is allowed to act on an acid aqueous solution having a predetermined concentration. After subjecting to hydrolysis treatment (hereinafter sometimes referred to as “hydrolysis treatment step”), the resulting hydrolyzed solution is neutralized (hereinafter also referred to as “neutralization step”). The residue is dried (hereinafter sometimes referred to as “drying step”) and purified from the residue (hereinafter referred to as “purification step”). This method is more preferable in that it can extract a large amount of the PT and / or PD and can be easily produced.

<< Hydrolysis treatment process >>
The hydrolysis treatment step is a step in which an acid aqueous solution having a predetermined concentration is allowed to act on the saponin-containing plant to hydrolyze the saponin in the plant to produce the PT and / or the PD. The hydrolysis treatment step is preferably performed in the presence of a lower alcohol.

-Saponin-containing plants-
Examples of the saponin-containing plants, if a natural product that contains saponins is not particularly limited and may be appropriately selected depending on the purpose, for example, Araliaceae (Araliaceae), Umbelliferae (Apiaceae), Polygalaceae ( Polygalaceae), bellflower family (Campanulaceae), Cucurbitaceae (Cucurbitaceae), legumes (Fabaceae), Amaranthaceae (Amaranthaceae), lardizabalaceae (lardizabalaceae), rhamnaceae (Rhamnaceae), Liliaceae (Liliaceae), dioscoreaceae (Dioscoreaceae) Plants belonging to These may be used alone or in combination of two or more.

Specific examples include Araliaceae ( Aralia ) (Taranoki, Udo, etc.), Uragi ( Eleutherococcus ) (Ezoukogi, Ukogi, Koshibura, etc.), Tochibaninjin ( Panax ) [American ginseng, Panax ginseng, Sancynin ginseng 7 ginseng), Tochibaninjin (Bamboo ginseng), etc.]; Ceratoceae ( Bupleurum ) [Firefly, Mishimasaiko, etc.]; Himehagi ( Polygala ) [Himehagi, Itohimehagi (Onji), Hirohasenega, etc.] ; bellflower family Campanulaceae genus (platycodon) [bellflower, etc.]; Cucurbitaceae Gynostemma pentaphyllum genus (Gynostemma) [Gynostemma pentaphyllum, etc.]; leguminous Glycyrrhiza (Glycyrrhiza) [licorice, etc.]; specific Yu family Achyranthes bidentata genus (Achyranthes) [Hinata Achyranthes bidentata (Goshitsu), etc.]; lardizabalaceae of Akebia genus (Akebia) [Mitsubaakebi (Mokutsuu), etc.]; rhamnaceae jujuba genus (Ziziphus) [Natsume (gymnastics), etc.]; lily Examples include Ophiopogon of the family [ Dioscorea , etc.]; Dioscorea [ Dioscorea ], etc.

  There is no restriction | limiting in particular as a site | part of the said saponin containing plant, According to the objective, it can select suitably, For example, a root, a rhizome, a leaf, a stem, a flower etc. are mentioned. Specific examples include: ginseng root, ginseng root, tochibanin ginseng root, sorghum root, arachnid root, udo root, mishima psyche root, himehimehagi root, hirohasenega root, kikyo root, amacha eel all Examples include grass, licorice root, chickweed root, honey bee stalk, jujube fruit, genus rhizome, jade beard root, onidokoro rhizome.

  Among these, the saponin-containing plant is preferably ginseng, ginseng root, ginseng root, root ginseng root, ginseng root ginseng root, sorghum root ginseng root, More preferably, the roots of the araliaceae genus taranoki, the roots of the arachnaceae genus genus genus, the whole plant of the cucurbitaceae genus genus amachazuru, and the highest yield of the above-mentioned PT and / or the above-mentioned PD is obtained. The root is particularly preferred.

  The saponin-containing plant may be used as it is collected from nature, for example, by using it after pretreatment appropriately combining washing, drying, cutting, crushing, pulverization, etc. It becomes possible to perform the hydrolysis treatment described later more efficiently. Among these, it is preferable to use a pulverized powdery plant as the saponin-containing plant. In addition, you may utilize a commercial item for the said saponin containing plant. Specific examples of the commercially available products include rice ginseng powder, rice ginseng water extract extract powder (both manufactured by Matsuura Pharmaceutical Co., Ltd.), and the like.

--Aqueous acid solution--
The aqueous acid solution is not particularly limited as long as it is an aqueous solution containing an acid, and can be appropriately selected according to the purpose. For example, an aqueous solution containing an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, or nitric acid is preferable. These may be used alone or in combination of two or more. Among these, an aqueous solution containing hydrochloric acid is more preferable.

  There is no restriction | limiting in particular as the density | concentration of the acid in the said acid aqueous solution, Although it can select suitably according to the objective, 0.01 mol / L-4 mol / L are preferable, and 0.5 mol / L-3 mol / L are more preferable. If the acid concentration is less than 0.01 mol / L, hydrolysis may be insufficient and the PT and / or PD may not be efficiently produced. If the concentration exceeds 4 mol / L, hydrolysis proceeds excessively. And it may be disadvantageous in terms of cost. On the other hand, when the concentration of the acid is within the preferable range, the PT and / or the PD can be efficiently generated by sufficient hydrolysis.

  There is no restriction | limiting in particular as the usage-amount of the said acid aqueous solution, Although it can select suitably according to the objective, It is preferable to use 2 to 20 times volume with respect to the said saponin containing plant. When the amount of the acid aqueous solution used is less than twice the capacity of the saponin-containing plant, the saponin-containing plant may not be sufficiently immersed and the hydrolysis treatment may be insufficient. The reaction may become saturated and disadvantageous in cost.

-Lower alcohol-
The hydrolysis treatment is more preferably performed in the presence of a lower alcohol. By using a lower alcohol in the hydrolysis treatment step, it is possible to improve the affinity between the saponin-containing plant and the acid aqueous solution, and to proceed the hydrolysis efficiently. In addition, the use of the lower alcohol is advantageous in that the taste and handleability of the obtained PT and / or PD can be improved.

  There is no restriction | limiting in particular as said lower alcohol, According to the objective, it can select suitably, For example, C1-C5 alcohol etc. are mentioned. These may be used alone or in combination of two or more. Among these, methanol, ethanol, and propanol are preferable, and ethanol is particularly preferable from the viewpoint of safety.

  When the lower alcohol is used as an aqueous solution containing the lower alcohol, the mixing ratio of water and the lower alcohol is not particularly limited and may be appropriately selected depending on the intended purpose. The lower alcohol is preferably 9: 1 to 2: 1 and more preferably 3: 1.

There is no restriction | limiting in particular as the usage-amount of the said lower alcohol, Although it can select suitably according to the objective, 1 volume%-80 volume% are preferable with respect to the total amount of a hydrolysis liquid, 10 volume%-50 volume % Is more preferable, and 20% by volume to 40% by volume is particularly preferable. When the amount of the lower alcohol used is less than 1% by volume with respect to the total amount of the hydrolyzed liquid, the PT and / or the PD may not be efficiently produced. The PT and / or the PD may not be generated efficiently or may be disadvantageous in cost. On the other hand, when the amount of the lower alcohol used is within the particularly preferable range, it is advantageous in that the PT and / or the PD can be efficiently generated.
The “total amount of hydrolyzed liquid” refers to the total amount of the reaction liquid including the acid aqueous solution and the lower alcohol.

  The total amount of the reaction solution including the acid aqueous solution and the lower alcohol (total amount of hydrolyzed solution) is preferably 2 to 20 times the volume of the saponin-containing plant. When the total reaction liquid amount is less than 2 times the volume of the saponin-containing plant, the saponin-containing plant may not be sufficiently immersed and the hydrolysis treatment may be insufficient. The reaction can become saturated and costly.

  There is no restriction | limiting in particular as processing temperature in the said hydrolysis process, Although it can select suitably according to the objective, 60 to 100 degreeC is preferable and 70 to 90 degreeC is more preferable. If the treatment temperature is less than 60 ° C, hydrolysis may be insufficient and the PT and / or PD may not be produced efficiently. If the treatment temperature exceeds 100 ° C, special production equipment is required. , May be disadvantageous in cost. On the other hand, when the treatment temperature is within the more preferable range, it is advantageous in that the PT and / or the PD can be efficiently generated.

  There is no restriction | limiting in particular as processing time in the said hydrolysis process, Although it can select suitably according to the objective, 30 minutes-24 hours are preferable, and 2 hours-8 hours are more preferable. If the treatment time is less than 30 minutes, hydrolysis may be insufficient and the PT and / or PD may not be efficiently produced. If the treatment time exceeds 24 hours, the reaction may proceed excessively, It may be disadvantageous in cost. On the other hand, when the processing time is within the more preferable range, it is advantageous in that the PT and / or the PD can be efficiently generated.

<< Neutralization process >>
The neutralization step is a step of neutralizing the hydrolyzed liquid obtained in the hydrolysis treatment step.
The neutralization method is not particularly limited and may be appropriately selected from known methods according to the purpose. For example, the hydrolyzed solution may contain sodium hydroxide, potassium hydroxide, or the like. It can be carried out by appropriately adding a strong base aqueous solution.
The pH after neutralization is not particularly limited as long as it is neutral, and can be appropriately selected according to the purpose, but is preferably 5 to 8.

<< Filtration process >>
The said filtration process is a process of filtering the liquid after the hydrolysis process after neutralizing in the said neutralization process, and isolate | separating into a filtrate and a residue.
There is no restriction | limiting in particular as said filtration method, According to the objective, it can select suitably from well-known methods. After filtration, washing with water may be repeated until there is no more salt. The washing with water is also preferable in that the alcohol concentration can be lowered.

-Hydrofiltration-
When the lower alcohol is not used in the hydrolysis treatment step, the neutralization can proceed to the filtration step as it is, but when the lower alcohol is used, the produced PT and / or before filtration. Alternatively, for the purpose of promoting the residue of the PD in the residue, it is preferable to add water to lower the lower alcohol concentration in the solution after the hydrolysis treatment.

  In this case, the amount of water to be added is preferably as large as possible, but the lower alcohol concentration in the solution after the hydrolysis treatment is preferably as low as possible. Specifically, it is preferably added so as to be 50% by volume or less. It is more preferable to add so that it may become 10% or less, and it is especially preferable to add so that it may become 10 volume% or less. If the lower alcohol concentration in the liquid after the hydrolysis treatment is subjected to filtration while exceeding 50% by volume, the produced PT and / or PD is dissolved in the lower alcohol and discharged as a filtrate, and the residue The content of the PT and / or the PD may be reduced. On the other hand, when the lower alcohol concentration in the liquid after the hydrolysis treatment is within the particularly preferable range, it is advantageous in that the content of the PT and / or the PD in the residue can be further increased.

-Filtration after concentration under reduced pressure-
Moreover, the lower alcohol concentration in the liquid after the hydrolysis treatment is lowered by distilling off the lower alcohol by vacuum concentration for the purpose of promoting the residual PT and / or PD produced in the residue before filtration. be able to.

  In this case, there is no restriction | limiting in particular as concentration temperature, Although it can select suitably according to the objective, 70 degrees C or less is preferable and 40 to 50 degreeC is more preferable.

  The concentration of the lower alcohol after concentration under reduced pressure is not particularly limited and may be appropriately selected depending on the intended purpose. It is preferably distilled off so as to be 50% by volume or less, and preferably 30% by volume or less. More preferably, it is more preferably distilled off to 10% by volume or less. If the lower alcohol concentration in the liquid after the hydrolysis treatment is subjected to filtration while exceeding 50% by volume, the produced PT and / or PD is dissolved in the lower alcohol and discharged as a filtrate, and the residue This is disadvantageous in that the content of the PT and / or the PD is reduced. On the other hand, when the lower alcohol concentration in the solution after the hydrolysis treatment is within the particularly preferable range, it is advantageous in that the content of the PT and / or the PD in the residue can be further increased.

  Moreover, although the said vacuum concentration and the said hydrofiltration may each be performed as a single process, you may perform as a series of processes. In this case, water is added to the liquid after concentration under reduced pressure, and the hydrofiltration is performed.

<< Drying process >>
The said drying process is a process of drying the residue after the said filtration process, and obtaining the dried material containing the said PT and / or the said PD.
The method for performing the drying is not particularly limited and can be appropriately selected from known methods according to the purpose. Examples thereof include a freeze-drying method, a ventilation drying method, a heat drying method, and a vacuum drying method. It is done.

<< Purification process >>
The purification step includes the PT and / or the hydrolyzed product obtained in the hydrolysis treatment step, preferably the residue produced through the neutralization step, the filtration step, and / or the drying step. This is a step of purifying the PD.
The purification method is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a purification method using a silica gel column. There is no restriction | limiting in particular as a method refine | purifying using the said silica gel column, According to the objective, it can select suitably, For example, the ethanol solution containing 1 mass%-5 mass% of the processed material obtained by acid hydrolysis Next, after removing insolubles using a filter paper or a centrifuge, it was further concentrated 5 to 10 times using a rotary evaporator and filled with silica gel (for example, silica gel 60N manufactured by Kanto Chemical Co., Inc.). Examples include a method in which the concentrated solution is added to a glass column and column separation is performed using chloroform: ethanol = 10: 1 (V / V) as an eluent.
On normal phase TLC using chloroform: ethanol = 10: 1 (V / V) as a developing solvent, a fraction corresponding to an Rf value of 0.4 was concentrated to obtain highly pure panaxatriol (PT). The fraction corresponding to the Rf value of 0.6 can be concentrated to obtain highly pure panaxadiol (PD).

<Other ingredients>
The other components in the adiponectin production promoter are not particularly limited as long as the effects of the present invention are not impaired, and can be appropriately selected according to the purpose. Examples thereof include additives, adjuvants, and water. It is done.

  The additive or the adjuvant is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include bactericides, preservatives, binders, thickeners, fixing agents, binders, and coloring agents. , Stabilizers, pH adjusters, buffers, isotonic agents, solvents, antioxidants, UV inhibitors, crystal precipitation inhibitors, antifoaming agents, physical property improvers, preservatives, vitamins, amino acids, fragrances Etc. These may be used alone or in combination of two or more.

  There is no restriction | limiting in particular as said disinfectant, According to the objective, it can select suitably, For example, cationic surfactants, such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride, etc. are mentioned.

  There is no restriction | limiting in particular as said preservative, According to the objective, it can select suitably, For example, paraoxybenzoic acid esters, chlorobutanol, cresol, etc. are mentioned.

  The binder, thickener, and fixing agent are not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include starch, dextrin, maltitol, cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, and hydroxyethylcellulose. , Hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethyl starch, pullulan, sodium alginate, ammonium alginate, propylene glycol ester alginate, guar gum, locust bean gum, gum arabic, xanthan gum, gelatin, casein, polyvinyl alcohol, polyethylene oxide, polyethylene glycol, Ethylene / propylene block polymer, sodium polyacrylate, sodium lauryl sulfate, polyethylene And vinyl pyrrolidone.

  The binder is not particularly limited and may be appropriately selected depending on the intended purpose. For example, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, hydroxypropylcellulose, hydroxy Examples include propyl starch, methyl cellulose, ethyl cellulose, shellac, calcium phosphate, calcium carbonate, calcium stearate, polyvinyl pyrrolidone, and stearic acid monoglyceride.

  The colorant is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include titanium oxide and iron oxide.

  The stabilizer is not particularly limited and may be appropriately selected depending on the intended purpose. For example, tragacanth, gum arabic, agar, gelatin, sodium pyrosulfite, EDTA (ethylenediaminetetraacetic acid), thioglycolic acid, thiol Examples include lactic acid.

  There is no restriction | limiting in particular as said pH adjuster and said buffering agent, According to the objective, it can select suitably, For example, sodium citrate, sodium acetate, sodium phosphate, sodium hydrogencarbonate etc. are mentioned.

  The tonicity agent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include sodium chloride and glucose.

  There is no restriction | limiting in particular as content of the said other component in the said adiponectin production promoter, According to the objective, it can select suitably.

<Application>
The adiponectin production promoter is highly safe, has an excellent adiponectin production promoting action, and can increase the amount of adiponectin in blood, so that insulin resistance causing diabetes, hyperlipidemia, hypertension, It can be suitably used for preventing or treating so-called lifestyle-related diseases such as arteriosclerosis.
Since the adiponectin production promoter is highly safe, it is preferably taken as a food or drink. As said food-drinks, the said adiponectin production promoter itself may be sufficient, and what was mixed with the other foodstuff may be sufficient.

<Dosage form>
There is no restriction | limiting in particular as a dosage form of the said adiponectin production promoter, According to the objective, it can select suitably, For example, an oral solid agent, an oral semi-solid agent, an oral liquid agent etc. are mentioned. Among these, since PT and PD have a bitter taste, oral solid preparations are preferable.

-Oral solid agent-
The oral solid preparation is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include tablets, coated tablets, granules, powders, capsules, troches, tablets and the like.
There is no restriction | limiting in particular as a manufacturing method of the said oral solid preparation, A normal method can be used, for example, it manufactures by adding the said PT and / or said PD, and also the said other component as needed. be able to.

-Oral semi-solid formulation-
The oral half-solid preparation is not particularly limited as long as it is located between the liquid preparation and the solid preparation, and can be appropriately selected according to the purpose. For example, a lozenge, chewing gum, whipping agent, jelly Agents and the like.
There is no restriction | limiting in particular as a manufacturing method of the said oral semi-solid preparation, A normal method can be used, for example, it adds by adding the said other component as needed, for example, the said PT and / or the said PD. can do.

-Oral solution-
There is no restriction | limiting in particular as said oral liquid agent, According to the objective, it can select suitably, For example, an internal use liquid agent, a syrup agent, an elixir etc. are mentioned.
There is no restriction | limiting in particular as a manufacturing method of the said oral liquid preparation, A normal method can be used, for example, manufacturing by adding the said other component as needed, for example, the said PT and / or the said PD. Can do.

<Food &Drink>
In the present invention, the food and drink are those that are less likely to harm human health and are taken by oral or gastrointestinal administration in normal social life. It is not limited to categories such as quasi-drugs, and includes, for example, a wide range of foods that are taken orally, such as general foods, health foods, health functional foods, quasi drugs, and pharmaceuticals.

  There is no restriction | limiting in particular as a compounding quantity of the said adiponectin production promoter in the said food / beverage products, It can mix | blend suitably according to the kind of object food / beverage products within the range which does not impair the effect of this invention. Moreover, the said food / beverage products may be the said adiponectin production promoter itself.

  There is no restriction | limiting in particular as said kind of food / beverage products, It can select suitably according to the objective, For example, drinks, such as a soft drink, a carbonated drink, a nutrition drink, a fruit drink, a lactic acid drink; Ice cream, ice sherbet, Frozen desserts such as shaved ice; noodles such as buckwheat, udon, harusame, dumpling skin, shumai skin, Chinese noodles, instant noodles; rice cakes, candy, gum, chocolate, tablet confectionery, snacks, biscuits, jelly, jam, cream, baked Sweets such as confectionery and bread; crab, salmon, clams, tuna, sardines, shrimp, skipjack, mackerel, whale, oyster, saury, squid, red scallop, scallop, abalone, sea urchin, salmon roe, tocobushi, etc .; Processed fishery and livestock products such as sausages; dairy products such as processed milk and fermented milk; salad oil, tempura oil, margarine, mayonnaise, short Oils and processed foods such as sauces, sauces, sauces, sauces, etc .; curry, stew, oyakodon, rice cakes, miso cooked, Chinese rice cakes, and rice cakes, tempura, rice cakes, coconut rice, oden, marvodorf Retort pouch foods such as beef bowl, meat sauce, egg soup, omelet rice, dumplings, shumai, hamburger, meatballs; various forms of health foods, nutritional supplements, pharmaceuticals, quasi drugs, and the like.

<Ingestion>
There is no restriction | limiting in particular as an ingestion method of the said adiponectin production promoter, ingestion amount, ingestion frequency, ingestion time, and ingestion object, According to the objective, it can select suitably.
There is no restriction | limiting in particular as said ingestion method, Although it can select suitably according to the objective, The method of ingesting orally is preferable at the point which can be ingested easily and is easy to ingest continuously.
The intake amount is not particularly limited and may be appropriately selected in consideration of various factors such as the age, weight, constitution, symptom, and presence / absence of administration of a drug containing another component as an active ingredient. it can.
The animal species to be ingested are those that are suitably applied to humans, but as long as the effects are exerted, animals other than humans, such as mice, rats, hamsters, birds, dogs, It is also possible to apply to cats, sheep, goats, cows, pigs, monkeys and the like.

  Whether or not the adiponectin production promoter increased the production of adiponectin in the blood was confirmed by, for example, collecting the blood to be ingested and measuring the blood by ELISA, Western blotting, etc. can do.

  EXAMPLES The present invention will be specifically described below with reference to examples of the present invention, but the present invention is not limited to these examples.

(Production Example 1)
<Preparation of processed ginseng acid products>
1 kg of ginseng powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) is suspended in 10 L of 25 wt% aqueous ethanol solution containing 5.9 wt% hydrochloric acid (2 mol / L hydrochloric acid) and reacted at 80 ° C. for 6 hours with slow stirring. I let you. Subsequently, after cooling this reaction liquid on ice, 5 mol / L sodium hydroxide aqueous solution was added and it adjusted to pH 7.0. Next, the pH-adjusted solution was diluted 10-fold with distilled water, suction filtered, and separated into a filtrate and a residue. The obtained residue was freeze-dried to obtain 180 g of a ginseng treated product.
When the contents of panaxatriol (PT) and panaxadiol (PD) in the obtained processed ginseng acid product were measured by the following method, PT was 5.0% by mass and PD was 5%. It was 5% by mass.

-Analysis of PT and PD-
About 0.1 g of the seven ginseng acid treated products were accurately weighed, added with about 8 mL of ethanol (purity 99.5% by volume), and suspended in an ultrasonic bath for 15 minutes. After centrifugation at about 700 × g for 10 minutes, ethanol (purity 99.5% by volume) was added to the supernatant to make exactly 10 mL. This liquid was measured by gas chromatography under the following conditions. The PT holding time under the following conditions was about 29 minutes, and the PD holding time was about 18 minutes.
[Analysis conditions]
Gas chromatograph: GC353B (GL Science Co., Ltd.)
Detector: Hydrogen flame ionization detector (FID)
Injection method: Split injection method (split ratio 1:50)
Column: DB-17MS (length 30 m, inner diameter 0.25 mm, film thickness 0.25 μm, manufactured by Agilent Technologies)
Column temperature: Initial temperature: 310 ° C
Initial temperature holding time: 20 minutes
Temperature increase rate: 10 ° C / min
Achieving temperature: 320 ° C
Achieving temperature holding time: 14 minutes Carrier gas: Helium Flow rate: 1.5 mL / min Inlet temperature: 320 ° C
Detector temperature: 320 ° C
Injection volume: 1 μL

  Panaxatriol standard product (manufactured by LKT Laboratories) and panaxadiol standard product (manufactured by LKT Laboratories) were prepared to 1 mg / mL, 0.5 mg / mL, and 0.1 mg / mL, respectively, and a calibration curve was prepared. A standard solution was prepared. The standard solution for calibration curve was measured by gas chromatography under the same conditions as described above using 1 μL each. Each peak area was measured, and a calibration curve was prepared from the peak area and concentration of each standard curve standard solution. Using this calibration curve, the contents of PT and PD in the processed ginseng acid product were measured.

<Separation of Panaxatriol (PT) and Panaxadiol (PD)>
An ethanol solution containing 3% by mass of the processed ginseng acid was prepared. Next, after removing insolubles using filter paper, the solution is further concentrated 8 times using a rotary evaporator, and the concentrated solution is added to a glass column packed with silica gel (silica gel 60N, manufactured by Kanto Chemical Co., Inc.), Column fractionation was performed using chloroform: ethanol = 10: 1 (V / V) as an eluent. On normal phase TLC using chloroform: ethanol = 10: 1 (V / V) as a developing solvent, the fraction corresponding to an Rf value of 0.4 was concentrated to obtain highly pure panaxatriol (PT). It was. Further, the fraction corresponding to an Rf value of 0.6 was concentrated to obtain highly pure panaxadiol (PD).

Example 1
Capsules containing 180 mg of the ginseng acid processed product produced in Production Example 1 were prepared, and healthy individuals (13 adult men and women) were ingested 1 capsule per day for 12 weeks (hereinafter referred to as “acid treated product intake group”). ”). Blood was collected before and 12 weeks after ingestion of the capsules, and the amount of adiponectin in the blood was measured. The amount of blood adiponectin before ingestion was compared with the amount of blood adiponectin 12 weeks after the start of ingestion, and the test was performed by Student's t test, and statistical analysis was performed as a significant difference at P <0.05.
The amount of adiponectin in the blood was measured using a human adiponectin ELISA kit (manufactured by Otsuka Pharmaceutical Co., Ltd.).

(Example 2)
Capsules containing 8 mg of panaxadiol separated and purified in Production Example 1 were prepared, and healthy individuals (12 adult men and women) ingested 1 capsule per day for 12 weeks (hereinafter referred to as “PD intake group”) There). Blood was collected before ingestion of the capsule and 12 weeks after the start of ingestion, and the amount of adiponectin in the blood was measured by the same method as in Example 1, and statistical analysis was performed.

(Example 3)
Capsules containing 8 mg of panaxatriol separated and purified in Production Example 1 were prepared, and healthy individuals (14 adult men and women) ingested 1 capsule per day for 12 weeks (hereinafter referred to as “PT intake group”) There). Blood was collected before ingestion of the capsule and 12 weeks after the start of ingestion, and the amount of adiponectin in the blood was measured by the same method as in Example 1, and statistical analysis was performed.

(Comparative Example 1)
In the preparation of the capsule of Example 1, a capsule was prepared in the same manner as in Example 1 except that 180 mg of the ginseng treated product was not added. This was given to healthy individuals (11 adult males and females) for 1 week for 12 weeks (hereinafter sometimes referred to as “control group”). Blood was collected before ingestion of the capsule and 12 weeks after the start of ingestion, and the amount of adiponectin in the blood was measured by the same method as in Example 1, and statistical analysis was performed.

The results of Examples 1 to 3 and Comparative Example 1 are shown in Table 1 below and FIG.
In addition, the reference value in humans of the amount of blood adiponectin is 4.0 μg / mL or more.

  From the results of Table 1 and FIG. 1, a significant increase in the amount of adiponectin in the blood was observed by ingesting the seven ginseng acid treated products, panaxadiol, or panaxatriol.

The adiponectin production promoter is highly safe, has an excellent adiponectin production promoting action, and can increase the amount of adiponectin in blood, so that insulin resistance causing diabetes, hyperlipidemia, hypertension, It can be suitably used for preventing or treating so-called lifestyle-related diseases such as arteriosclerosis.
Moreover, since the adiponectin production promoter has high safety, it can be suitably used as a food or drink.

Claims (3)

  An adiponectin production promoter characterized by containing at least one of panaxatriol and panaxadiol and promoting the production of adiponectin.   The adiponectin production promoter according to claim 1, wherein at least one of panaxatriol and panaxadiol is sapogenin derived from ginseng ginseng.   The adiponectin production promoter of Claim 2 obtained by hydrolyzing the sapogenin derived from Scarinae ginseng in the presence of 0.01 mol / L to 4 mol / L acid aqueous solution and a lower alcohol.